Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic
Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic
复制标题
DOI：
10.1016/j.cca.2015.02.036
复制
发表时间：
2015-04-15
影响因子：
5
通讯作者：
Fuchsova, Radka
中科院分区：
文献类型：
--
作者：
Kucera, Radek;Topolcan, Ondrej;Fuchsova, Radka
背景：IGF1负责调节人类细胞的生长、代谢和分化。IGFBP3是血液中含量最丰富的IGFI载体蛋白。IGF1/IGFBP3摩尔比是衡量IGF1生物利用度的指标。我们决定为捷克成年人群创建一个IGF1、IGFBP3和IGF1/IGFBPP3比值的参考范围文件。方法：我们从捷克几个地区选择了1022名受试者，男性467人，女性555人(年龄20-98岁)。这组人包括献血者和接受定期预防性检查的患者。使用以下放射免疫试剂盒检测血清IGF1和IGFBP3水平：IRMA IGF1(免疫技术公司，法国马赛)和IRMA IGFBP3(免疫技术公司，布拉格，捷克共和国)。计算了IGF1/IGFBP3比值。以下患者组被排除在外：糖尿病、高血糖、高胰岛素水平的患者、手术后患者、多病患者和肿瘤疾病患者。受试者被分成7个年龄组。评估了不同年龄段每十年观察到的分析物水平的变化。结果：3个参数IGF1、IGFBP3和IGF1/IGFBP3均随年龄的降低而降低：P<；0.0001，r分别为0.64、0.35和0.54。下降的动态在男性和女性之间是不同的。图1显示了以年龄为自变量的性别回归模型。图2(a，b，c)显示了IGFI、IGFBP3和IGF1/IGFBP3随年龄变化的非参数参考区间曲线(中位数和2.5%-97.5%)。所有中位数和第2.5~97.5个百分位数用三次样条法绘制。男性的线性回归模型为：IGFI=291.34619-2.41211 x年龄，IGFBP3=2931.62778-6.11659 x年龄，IGF1/IGFBP3=0.02897-0.00021213 x年龄。女性IGF1=241.67406-1.98466 x年龄，IGFBP3=3688.60561-16.39560 x年龄，IGF1/IGFBP3=0.02029-0.00013233 x年龄。在P<；0.0001(Wilcoxon检验)的男性中，IGF1在统计学上显著升高，但下降得更快(p=0.0121)。IGFBP3在女性中显著升高，p=0.0004(Wilcoxon检验)，但下降速度更快(p<；0.0001)。在P<；0.0001(Wilcoxon检验)的男性中，IGF1/IGFBP3显著升高，但下降的速度更快(P<；0.0001)。结论：作者建议使用基于IGF1、IGFBP3和IGF1/IGFBP3比值参考范围的线性回归模型，并对性别使用不同的参考范围。(C)2015爱思唯尔B.V.保留所有权利。
Background: IGF1 is responsible for regulation of growth, metabolism and differentiation of human cells. IGFBP3 is the most abundant of the carrier proteins for IGFI in the blood. IGF1/IGFBP3 molar ratio is an indicator of IGF1 bioavailability. We decided to create a file of reference ranges of IGF1, IGFBP3 and IGF1/IGFBPP3 ratio for the adult Czech population across the age spectrum.Methods: We selected a group of 1022 subjects, 467 males and 555 females (ages 20-98 years), from several regions in the Czech Republic. The group consisted of blood donors and patients undergoing regular preventive examinations. Serum levels of IGF1 and IGFBP3 were measured using the following radioimmunoassay kits: IRMA IGF1 (Immunotech, Marseille, France) and IRMA IGFBP3 (Immunotech, Prague, Czech Republic). The IGF1/IGFBP3 ratio was also calculated. The following groups of patients were excluded: patients with diabetes, high blood glucose, high insulin levels, post-surgery patients, polymorbid patients, and subjects with oncological diseases. Subjects were divided into seven age-groups. Changes in the levels of observed analytes in each decade across the age spectrum were evaluated. All statistical analyses were performed by SAS 9.3 (Statistical Analysis Software release 9.3; SAS Institute Inc., Cary, NC, USA).Results: All three parameters IGF1, IGFBP3 and IGF1/IGFBP3 decreased in parallel with decrease in age: p < 0.0001, r = 0.64, 0.35 and 0.54, respectively. The dynamics of the decline was different between males and females. Linear regression models with age as independent variable fitted by gender are displayed in Fig. 1. Nonparametric reference interval curves (medians and 2.5th-97.5th percentiles) for IGFI, IGFBP3 and IGF1/IGFBP3 ratio as function of age by gender are displayed in Fig. 2(a,b,c). All medians and 2.5th-97.5th percentiles were plotted by cubic spline. For males, linear regression models were as follows: IGFI = 291.34619 - 2.41211 x age, IGFBP3 = 2931.62778 - 6.11659 x age, IGF1/IGFBP3 = 0.02897 - 0.00021213 x age. For females, we plotted the following: IGF1 = 241.67406 - 1.98466 x age, IGFBP3 = 3688.60561 - 16.39560 x age, IGF1/IGFBP3 = 0.02029 - 0.00013233 x age. IGF1 was statistically significantly higher in males with p < 0.0001 (Wilcoxon test) but decreased faster (p = 0.0121). IGFBP3 was statistically significantly higher in females with p = 0.0004 (Wilcoxon test) but decreased faster (p < 0.0001). IGF1/IGFBP3 was statistically significantly higher in males with p < 0.0001 (Wilcoxon test) but decreased faster (p < 0.0001).Conclusion: Authors recommend using of a linear regression model based reference ranges for IGF1, IGFBP3 and IGF1/IGFBP3 ratio and using different reference ranges for genders. (C) 2015 Elsevier B.V. All rights reserved.